“Amylin agonism has shown great potential to provide clinically meaningful weight loss and may also provide additional improvements in glycaemic control in people with overweight or obesity and type 2 ...

Bristol-Myers Squibb Co. has announced it will acquire Amylin Pharmaceuticals for approximately US $5.3 billion in cash. Following the completion of this acquisition, Bristol-Myers Squibb will ...

It has been announced that following Bristol-Myers Squibb’s (BMS) successful acquisition of Amylin Pharmaceuticals, AstraZeneca (AZ) has made an initial payment of approximately US $3.2 billion ...

Strategic updates include the acquisition of Nimble Therapeutics and a licensing agreement with Gubra to develop an amylin analog for obesity treatment. These initiatives underscore AbbVie’s ...

During the quarter, the company also made progress with its newest program evaluating a series of internally developed agonists of the amylin receptor, which have demonstrated improvements in body ...

In a $1.65 billion upfront deal with Zealand Pharma signed in March, Roche gained the right to codevelop and co-commercialize long-acting amylin analog petrelintide in the weight-loss field.

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren ...

Adjusted Earnings Per Share (EPS): $2.46, $0.10 above guidance midpoint. Total Net Revenues: Over $13.3 billion, $550 million ahead of expectations. Ex-Humira Platform Sales Growth: More than 21% ...

It took until March to agree the deal with Roche. Petrelintide is based on the gut hormone amylin that makes you feel fuller for longer. The companies will develop it as a standalone drug and as a ...

The recent Gubra licensing deal brings rights to phase 1 amylin drug ABBV-295, which has had impressive data in obesity over a six-week time horizon at a relatively low 2 mg weekly dose.

Skyrizi and Rinvoq use in gastroenterology grew over 40% year-over-year. Cantor gave AbbVie an Overweight rating with a $210 price target. Feel unsure about the market’s next move? Copy trade ...

Delivers First-Quarter Net Revenues of $13.343 Billion, an Increase of 8.4 Percent on a Reported Basis or 9.8 Percent on an Operational Basis "AbbVie's first-quarter results were well ahead of our ...